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Abstract: Cholera toxin (CT) and the heat-labile enterotoxin of E. coli (LT), as well as 
their non toxic mutants, are potent mucosal adjuvants of immunization eliciting mucosal 
and systemic responses against unrelated co-administered antigens in experimental models 
and in humans (non toxic mutants). These enterotoxins are composed of two subunits, the 
A subunit, responsible for an ADP-ribosyl transferase activity and the B subunit, 
responsible for cell binding. Paradoxically, whereas the whole toxins have adjuvant 
properties, the B subunits of CT (CTB) and of LT (LTB) have been shown to induce 
antigen specific tolerance when administered mucosally with antigens in experimental 
models as well as, recently, in humans, making them an attractive strategy to prevent or 
treat autoimmune or allergic disorders. Immunomodulation is a complex process involving 
many cell types notably antigen presenting cells and regulatory T cells (Tregs). In this 
review, we focus on Treg cells and cholera-like enterotoxins and their non toxic derivates, 
with regard to subtype, in vivo/in  vitro  effects and possible role in the modulation of 
immune responses to coadministered antigens. 
Keywords:  cholera-like enterotoxins;  regulatory T cells;  cholera toxin;  heat-labile 
enterotoxin of E. coli; CTB; LTB 
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1. Introduction 
Cholera toxin (CT) from Vibrio cholerae  and the related heat-labile enterotoxin (LT) from 
toxinogenic strains of E. coli are both A: B5 ADP-ribosylating exotoxins that cause abundant secretory 
diarrhea and enhance bacterial pathogenicity. They are also extremely potent immunogens and 
mucosal and parenteral adjuvants of immunization that potentiate mucosal and systemic B and T cell 
responses against unrelated co-administered antigens (Ags) in many experimental models (reviewed 
in [1–5]). Both toxins comprise a single A subunit responsible for the ADP-ribosyl transferase activity 
and five identical B subunits, responsible for cell binding. Another group of enterotoxins that are 
expressed by E. coli strains and have the same structure as CT and LT includes LT-IIa and LT-IIb  
(type II subfamily, CT and LT representing the type I subfamily) [6,7]. To overcome the enterotoxicity 
and use them as adjuvant in humans, non toxic mutants of the A subunit that retain adjuvant properties 
have been developed [1–5] and in some cases tested in clinical trials [8–12].  
The B subunit of these toxins is devoid of toxicity and thus could also be used as adjuvants in 
humans. However, the adjuvant activity of the B subunit has been early a source of controversy and the 
question remains confusing. Moreover, the B subunits of CT (CTB) and LT (LTB), paradoxically, 
have been shown to promote tolerance to heterologous antigens. CTB has been the most studied, 
especially as conjugates with antigens and it has been proposed as a strategy to prevent auto-immune 
and allergic diseases [13] and has been tested in clinical assays [14]. 
On the whole, these molecules (the whole toxins, their non toxic mutants or the B subunits) are 
potent immune modulators which are involved in complex interactions with the immune system, 
leading either to increase or decrease immune responses.  
Many studies have reported about the effects of the whole toxins or their mutants on different innate 
or adaptive immune cells that could explain the adjuvant effect (reviewed in [1–5,15]). However, the 
precise mechanism of action of these adjuvants has not been completely elucidated. 
Different effects of the B subunit of these toxins on immune cells have also been reported but, 
conversely to the whole toxins and, because they potentiate tolerance and activation of regulatory  
T cells (Tregs) is a major mechanism involved in tolerance induction, the impact on Tregs has often 
been hypothesized, notably for CTB.  
The aim of this review is to make a point on what is known about Tregs and the cholera-like 
enterotoxins, including the whole molecules or their mutants as well as their subunits.  
First, the structures of these molecules will be described to underline similarities and differences 
which may impact the immunomodulatory properties, as well as the different regulatory T cell types.  
2. Structure of Cholera-Like Enterotoxins and Toxicity 
Whole toxins. CT and LT are highly homologous (80% AA homology). They are made of a single 
A subunit which is associated to a non covalently linked pentameric ring of B subunit (A:B5). The A 
subunit is enzymatically active and consists of two chains A1 and A2 joined by a proteolytically 
sensitive peptide (Arg192) joined by a disulphide bond which has to be reduced for full enzymatic 
activity [5]. The main receptor for the B subunit of both CT and LT is GM1-ganglioside [16] that is 
found ubiquitously on the surface of mammalian cells, including enterocytes and immune cells, Toxins 2010, 2                     
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dendritic cells, macrophages, B and T cells. Other interactions have been reported which may have 
importance in immunological functions. Notably CTB and LTB also bind to GD1b-ganglioside but 
with a lower affinity and LTB, that binds to GM1 with a lower affinity than CTB, has been shown to 
have wider receptor specificity, as it binds notably to GM2 and asialo-GM1 [17]. The A1 fragment 
enters the cell cytosol and catalyses ADP-ribosylation of Gsa (GTP-binding protein family) which 
irreversibly activates adenylate cyclase and leads to an elevation in cyclic adenosine monophosphate 
(cAMP) levels. cAMP causes protein kinase A (PKA) to phosphorylate and open the cystic fibrosis 
transmembrane regulator (CFTR) Cl- channel, thus water and Cl- are flushed out causing diarrhea. The 
A2 fragment represents an adaptor molecule which interacts with the B subunit and may be involved in 
delivery of the A1 fragment into the correct cellular compartment and may also have a role in 
modulating the immunological effects.  
The type II subfamily (LT-II) includes two variants, LT-IIa and LT-IIb, that show high homology to 
CT and LT but recognize different ganglioside receptors, notably the B subunit of LT-IIb binds to 
Gd1a ganglioside [18]. 
Mutants.  Site-directed mutagenesis has permitted the generation of mutants that have reduced 
toxicity. Mutants have been constructed to dissociate the enterotoxic effects from their adjuvant 
activity. Mutations in both the active and protease sites of CT and LT have been performed including 
peptide extension and amino acid deletion [1,3,5]. These mutants have been shown to possess adjuvant 
activity in animal models and some of them, the protease site mutant of LT, LT-R192G [8–10] and the 
enzymatic site mutant LTK63 [11,12] have been tested in humans. Another approach to detoxify CT 
has been proposed by Agren et al. [19] by linking the enzymatically active A subunit domain of the 
toxin to a synthetic analog of the Staphylococcus aureus protein A. The fusion protein devoid of the B 
subunit cannot bind to ganglioside receptors. CTA1-DD binds B cells, is non toxic despite enzymatic 
activity and has been shown to have adjuvant activity in animal models, notably after mucosal 
administration with chlamydial Major Outer Membrane Protein (MOMP), rotavirus VP6 chimeric 
protein and HIV1 envelope glycoproteins or as a fusion protein containing tandem repeats of the 
influenza matrix protein 2 (M2e) ectodomain epitope (CTA1-3M2e-DD) [20–23]. Of interest, two 
recent studies have reported that  enzymatically inactive mutants fusion proteins of CTA1-DD 
containing either a type II collagen peptide CTA1R7K-COL-DD or an OVA peptide CTA1R7K-OVA-DD 
induced tolerance [24,25]. 
B subunits. To avoid toxicity, CTB and LTB have been examined for their ability to augment 
immune responses to heterologous antigens. Devoid of enzymatic activity, they are responsible for cell 
binding. However, CTB and LTB have been shown to promote tolerance to coadministered antigens. 
They have been used either coadministered with antigens or as antigen-conjugates, especially CTB. 
The binding of LT-IIb B subunit to GD1a ganglioside facilitates TLR2 recruitment and activation and 
probably confers on the molecule its specific proinflammatory potential and its adjuvant activity [18]. 
This observation highlights the importance of cell binding in immunomodulatory properties of   
these molecules. 
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3. Regulatory T cells (Figure 1) 
Immunosuppression is an intrinsic property of the immune system and is partially mediated by  
T cells. The best defined T-cell population with immunosuppressive activity is the naturally activated 
subset of CD4
+ T cells (nTregs), that constitutively express the interleukin (IL)-2Rα chain CD25 and 
Foxp3 (forkhead box p3) transcription factor, which controls the development and function of nTregs. 
These thymus-derived suppressor cells are present in normal individuals, contribute to the maintenance 
of self tolerance and protect from a variety of autoimmune diseases. They are also implicated in 
immune responses against pathogens [26,27]. nTregs exert suppressive effects via cell-cell contact or 
via cytokines, IL-10 and transforming growth factor β (TGFβ). 
Regulatory T cells can also be induced from naïve peripheral CD4
+CD25
- T cells after antigenic 
exposure. Induced Tregs include three subtypes, CD4
+CD25
+Foxp3
+, Tr1 and Th3 regulatory T cells 
and their induction depends on the nature of the antigen, the context of antigen presentation, especially 
the type of dendritic cells, and the specificities of the tissue in which the antigen is delivered [28].  
CD4
+CD25
+Foxp3
+ iTregs have been generated in vitro and in vivo after TCR stimulation in the 
presence of IL-2 and TGFβ, under a variety of conditions. The gut-associated lymphoid tissue 
(GALT), which is a TGFβ-rich environment and contains a particular subset of dendritic cells 
producing retinoic acid, favors the development of CD4
+CD25
+Foxp3
+ iTregs. Moreover, studies have 
shown that nTregs and iTregs work in synergy to protect the host [29].  
Tr1 cells have been generated in vitro from naïve T cells in the presence of IL-10 and antigen. They 
have been shown to prevent colitis induced in SCID mice [30] and to be involved in suppressing 
immune responses towards food antigens. Classically, they produce high levels of IL-10 and no IL-4, 
but depending on experimental conditions, they can also secrete high amounts of TGFβ and IL-5 and 
low amounts of IFNγ and IL-2. Tr1 cells have no specific marker but are Foxp3
-CD25
low. They exert 
their suppressive effect via IL-10 and TGFβ [31]. 
Th3 cells are specifically triggered during oral tolerance. They express Foxp3 and secrete high 
amounts of TGFβ and some Th3 clones can produce IL-10 and IL-4. Moreover, they seem dependent 
on IL-4 (rather than IL-2) for growth. TGFβ plays a fundamental role in the normal intestine where it 
is abundant and TGFβ1 is an important mediator of epithelial cell differentiation and IgA class 
switching and it has immunosuppressive effects on lymphocytes. Moreover, TGFβ seems to be the link 
between the three induced Tregs mentioned above [32]. 
Besides CD4
+ Tregs, several types of CD8
+ Tregs have also been reported [33]. As CD4
+ Tregs, 
some CD8
+ Tregs express Foxp3 and CD25, others exert a suppressor effect via TGFβ or via IL-10. 
CD8
+ Tregs recognizing peptides associated with the MHC class Ib molecule Qa-1 and implicated in 
protection from experimental auto-immune encephalomyelitis (EAE) have also been reported. 
Moreover, in the intestine, intestinal intraepithelial lymphocytes (IEL) have been shown to have 
suppressive properties as TCRγδ IEL that secrete TGFβ and TCRαβ CD8αα IEL that secrete IL-10. 
Finally, CD8
+ Tregs with suppressive properties are also present in the intestinal lamina propria [28]. 
   Toxins 2010, 2                     
 
 
1778 
Figure 1. Generation of effector and regulatory T cells. Naïve CD4
+ and CD8
+ T cells as 
well as CD4
+ and probably also CD8
+ nTregs leave the thymus for the periphery where 
they colonize secondary lymphoid tissues and organs. A. Interaction between dendritic 
cells and naïve CD4
+ T cells leads to different effector T cells (Th1, Th2 and Th17) and 
induced regulatory T cells (iTreg: Tr1, Th3 and CD4
+CD25
+Foxp3
+ Tregs) depending on 
the cytokines produced in the micro-environment. Tregs modulate CD4
+ and CD8
+ effector 
responses via cell-cell contact or via cytokines, mainly IL-10 for Tr1 and TGFβ for Th3. B. 
As for CD4
+ T cells, several induced CD8
+ regulatory T cell subtypes have been reported: 
CD8
+CD25
+Foxp3
+ T cells similar to CD4
+ iTregs, Th3-like and Tr1-like CD8
+ Tregs.  
 
Abbreviation: RA: retinoic acid. 
4. Adjuvanticity of Cholera-Like Enterotoxins 
Many studies have reported on the mechanisms that could explain the adjuvant properties of CT and 
LT (reviewed in [1–5,15]). Effects on the epithelium (as a mechanical barrier and as a source of 
mediators) and on antigen presenting cells (APC) (dendritic cells (DC), macrophages and B cells) as 
well as the more recently described effect of LT-IIb B on TLR2 [18]  are easy to correlate with 
adjuvanticity. Other effects such as CT or LT-induced cell death are more difficult to interpret because 
of a great complexity (different in vivo/in  vitro  results, importance of the state of maturation or 
activation of lymphocytes [34]). Finally, two recent studies suggested additional mechanisms for 
adjuvanticity. Lee et al. have reported that CT induced strong Th17-type responses through intranasal 
delivery [35], whereas CT was thought to induce anti-inflammatory responses (by promoting Th2 and 
inhibiting Th1 responses). Moreover, the CTB subunit may be responsible for the CT’s ability to induce 
Th17-dominated responses which is in contradiction with the tolerogenic role of CTB. Another study by Toxins 2010, 2                     
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Tamayo  et al.  [36]  demonstrated that LT upregulates the expression of the glucocorticoid-induced 
TNFR-related protein (GITR) in CD4
+ T cells, that may contribute to adjuvanticity by acting as an 
activation-induced costimulatory signal in CD4
+CD25
- cells. Of note, this effect was observed after 
systemic but not mucosal administration of LT, thus demonstrating that the mechanisms of 
adjuvanticity of LT are influenced by the route of administration. 
5. Tolerogenicity of Cholera-Like Enterotoxins 
The B subunit of both CT and LT has been shown to promote tolerance to heterologous antigens. 
Tolerogenicity induced by CTB or LTB may result from a direct depletion of effector T cells as the B 
subunits of CT and LT have been shown to induce CD4
+ and CD8
+ T cell apoptosis [5]. Another 
mechanism has been recently proposed by Wang et al. who showed that GM1 cross-linking by CTB 
resulted in the transient receptor potential canonical (TRPC) 5 channel activation which mediated Ca
2+ 
influx in effector T cells and contributed to autoimmune suppression in an EAE model [37]. This effect 
mimics that of activated Tregs via Gal-1 on effector T cells.  
As a matter of fact, the most studied tolerogenic mechanism is the involvement of Tregs directly or 
via modulating APC. 
6. Cholera-Like Enterotoxins and Tregs 
As previously indicated, the generation and involvment of Tregs in immune modulation after 
administration of cholera-like molecules has been mainly hypothezised and studied with CTB or LTB 
coadministered with or conjugated to antigens, based on the tolerogenic properties of such Ag delivery 
systems. However, despite the great number of studies reporting on the effects of CT and LT on 
immune cells, few studies have looked at their impact on Tregs.  
6.1. B Subunits 
6.1.1. a-CTB  
Many studies have reported that CTB induces tolerance against heterologous antigens and this 
strategy has been proposed to prevent auto-immune diseases such as EAE, diabetes, arthritis, uveitis or 
allergic diseases [38]. Some studies have examined the roles of Tregs; they are listed in Tables 1 and 2. 
Most used Ag-CTB conjugates. 
Concerning auto-immune diseases (Table 1), Tregs have been proposed to be involved in the 
protection from clinical disease after immunization with Ag-CTB conjugates by the oral or the nasal 
route as well as intraperitoneally, in animal models of EAE, diabetes and uveitis. All together, despite 
different doses and protocols used, these studies report the involvement of Treg cells, notably CD4
+ 
Tregs, as demonstrated by their capacity to inhibit effector T cells in vitro and /or transfer experiments 
in vivo. Most of them underlined a decrease in Th1 and a shift to Th2 and/or Th3 T cells with IL-10, 
IL-4 and TGF production being increased. One study reported about CD4
+CD45RC
+RT6 memory 
regulatory T cells [38]. Of note, a dose-  dependent effect was reported in two studies [39,40]. Toxins 2010, 2 
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Table 1. CTB and regulatory T cells in auto-immune and inflammatory disease models. 
Model  Antigen  Protocol  Effects 
Proposed Mechanism  
for Tolerance 
Reference 
NOD mice 
Experimental 
diabetes 
Hu insulin-
CTB 
Oral 1 dose 2–20 µg + 
transfer  
Protection from clinical diabetes; Suppression of beta cell 
destruction 
Transfer of splenocytes induces protection  
Protective T cells Non characterized  [42] 
NOD mice 
Experimental 
diabetes 
Hu insulin-
CTB 
Oral 1 dose 10 µg + 
transfer  
Increase in IL-4 (Th2); decrease in IFNγ (Th1) in pancreatic 
LN + increase in TGFβ in MLN  
Transfer of CD4
+ (but not CD8
+) splenocytes induces 
protection 
Ag specific CD4
+ Tregs in the 
pancreas and draining LN Non 
characterized 
[43] 
NOD mice 
Experimental 
diabetes 
Hu insulin- 
CTB 
Nasal 1 dose 1 µg + 
transfer  
Delays the incidence of diabetes ; dose-dependent effect; 
IL10 and TGFβ increase in pancreas 
Transfer of CD4
+ splenocytes induces protection  
CD4
+ Tregs  
Non characterized  
Dose-dependent effect 
[39] 
H2d-RIP-
LCMV-NP 
transgenic mice 
(LCMV induced 
diabetes)  
Hu insulin-
CTB or 
Porcine-
insulin 
CTB  
Oral 0.1-10 µg 
Biweekly (7 wks) + 
transfer  
Transfer of splenocytes induces protection from diabetes 
and to bystander OVA antigen 
CD4 depletion abrogates protection  
Dose- dependent effect (only intermetiate dosages are 
protective) 
CD4
+ Tregs  
Non characterized  
Dose- dependent effect  
[40] 
NOD mice 
Experimental 
diabetes 
CTB alone 
IP 10 µg 3 times a 
week (4 weeks) + 
transfer  
Decreases the development of clinical diabetes 
Transfer of splenocytes inhibits the adoptive transfer of 
diabetes by spleen cells from diabetic mice into irradiated 
NOD mice 
Regulatory cells  
Non characterized 
[44] 
Rat EAE  MBP-CTB 
Oral 50 µg 3 doses 4, 6 
and 8 days after EAE 
induction transfer of 
MLN cells 
Protection from clinical EAE; Decrease in CD4, CD8, IL-2R 
and MHC class II in spinal cord + Decrease in IFNγ, IL-12, 
TNFα, MCP-1 and RANTES  
Increase in TGFβ 
Transfer of MLN cells induces protection  
Protective TGFβ producing 
regulatory T cells  
Non characterized 
[45] 
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Table 1. Cont. 
Rat 
experimental 
uveitis 
Pept-
HSP60- 
CTB 
Oral 5 doses 15µg on 
alternate days Transfer 
of MLN cells 
Increase in regulatory CD4
+CD45RC
lowRT6
+ subset of Th2 
memory in MLN and spleen  
Increase in IL-10, TGFβ, decrease in IFNγ and IL-12 in the 
MLN and the uveal tract  
Prevention of uveitis  
Transfer of MLN cells induces protection 
Regulatory subset of memory cells  
Shift from Th1 to Th2 and Th3 in 
the MLN and the uveal tract Non 
characterized 
[38] 
Apoe(-/-) mice 
atherosclerosis 
inflammatory 
disease model 
Peptide 
apolipopt 
B-100-
CTB 
Nasal 15µ g twice 
weekly12 weeks 
Reduces aortic lesion size  
Induction of Tregs CD4
+ IL-10+ (Tr1)TGF independent  
Tr1 Tregs  [41] 
Abbreviations: EAE: experimental auto-immune encephalomyelitis; HSP : heat-shock protein; MBP: myelin basic protein; MLN: mesenteric lymph nodes. 
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Besides TGFβ  producing Tregs, Tr1 Tregs have been recently reported in vaccination against 
atherosclerosis in mice [41]. Atherosclerosis is an inflammatory disease with auto-immune effectors 
contributing to disease progression. Intranasal immunization with apoB-CTB induced IL-10 producing 
Tr1 that inhibited effector responses to apoB-100 and reduced atherosclerosis. Moreover, these effects 
were TGFβ independent. 
In summary, these studies show that Ag-CTB conjugates induce protective regulatory T cells in 
animal models of auto-immune or inflammatory diseases. Although not fully characterized TGFβ 
producing CD4
+ Tregs (Th3 subtype?) have been most often reported in diabetes, EAE and uveitis, 
whereas in the atherosclerosis model, IL-10 producing Tr1 cells may be the major subtype involved. 
CD4
+CD25
+Foxp3
+  T cells have not been reported nor CD8
+  Tregs. Of note, variable doses and 
protocols of immunization have been used. 
Concerning allergic diseases (Table 2), the administration of Ag conjugated to CTB has been 
shown to suppress IgE responses and to induce therapeutic effects [38]. The models used either   
OVA-CTB (dietary antigen) or the inhalant allergen Betv1a-CTB (major birch pollen allergen) as 
antigens, by the oral, the nasal or the sublingual route. Again, different doses and protocols were used. 
A role for Tregs has been reported.  
Sun et al. [46] showed that oral tolerance induced by OVA-CTB was associated with an increase in 
TGFβ in serum and an increase in both the frequency and suppressive capacity of Foxp3
+CD25
+ Tregs 
together with the generation of both Foxp3
- and Foxp3
+CD25
-CD4
+ Tregs. The coadministration of CT 
together with OVA-CTB abolished the increase in frequency of Tregs. The same authors reported that 
sublingual administration of OVA-CTB can also efficiently suppress peripheral effector T cell 
responses to OVA associated with a strong increase in serum TGFβ levels, Foxp3
+CD25
+CD4
+ Treg 
cells and to a progressive depletion of effector T cells by apoptosis [47,48]. Effector T cell apoptosis 
was found to be critically dependent on CD25
+ Treg cells but independent of IL-10 production. In 
contrast, Bublin et al. [49], using the Betv1a-CTB conjugate by the intranasal route in a model of 
allergic sensitization, showed that upregulation of Foxp3, IL-10 and TGFβ mRNA expression was 
detected in splenocytes but only after pretreatment with unconjugated allergen and not with the fusion 
molecule, indicating that antigen conjugation to a mucosal carrier modifies the immunomodulating 
properties of an antigen/allergen. Of note, opposite effects on IgE production, lymphocyte proliferation 
and cytokine production had already been reported by Wiedermann et al.  [50]  after intranasal 
administration of OVA-CTB and rBetv1a-CTB. Moreover, intranasal
  administration prior to 
sensitization of unconjugated allergens also
 showed contrasting effects: OVA could not significantly
 
influence antigen-specific antibody or cytokine production,
  whereas intranasal pretreatment with 
unconjugated Betv1a suppressed
 allergen-specific immune responses in vivo and in vitro.  
George-Chandy et al. (2006) [51] using a different Ag-conjugate, i.e., a peptide from influenza 
haemagglutinin (HApep)-CTB conjugate, reported that CTB-induced oral tolerance could not be 
explained by CD25
+ dependent regulatory activity, as oral administration of HApep-CTB to mice 
depleted of CD25
+ cells still gave rise to systemic tolerance.  
 Toxins 2010, 2 
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Table 2. CTB and regulatory T cells in allergic disease models. 
Model  Antigen  Protocol  Effects 
Proposed Mechanism  
for Tolerance 
Reference 
BALB/c 
mice 
OVA-CTB 
Intragastric 3 doses (200 µg) 
at 2 days of interval  
Transfer of splenocytes and 
MLN cells 
Increase in the frequency and suppressive activity of Ag-specific 
CD25
+CD4
+Foxp3
+ Tregs (MLN, PP and spleen) abolished by the 
coadministration of CT (table 4)  
Generation of both Foxp3
+ and Foxp3
-CD25
-CD4
+  
Increase in TGFβ (serum) CD25
+ and CD25
- T cells suppress-effector 
Tcell proliferation in vitro - OVA-specific T cells and DTH after adoptive 
transfer 
Foxp3
+CD25
+CD4
+Tregs Foxp3
+and 
Foxp3
-CD25
-CD4
+Tregs 
[46] 
BALB/c 
mice 
OVA-CTB 
Sublingual  
One or 3 doses  
(40 µg) 
Increase in Tregs in CLN MLN, spleen Increase in TGFβ (serum) 
Suppression of proliferative responses to OVA in vitro Suppression of 
OVA-specific DTH responses in vivo and T-cell proliferative responses in 
mice immunized SC with OVA + CFA 
Foxp3
+CD25
+CD4
+ Tregs   [47] 
BALB/c 
mice 
OVA-CTB 
Sublingual  
Adoptive transfer of OVA-
specific TCR transgenic 
CD4
+ T cells 3 doses (40 µg 
or 60 µg) at 2-day intervals. 
Development of OVA-specific Foxp3
+CD25
+CD4
+ Tregs Suppression of 
peripheral T cell responses to OVA  
Apoptosis of OVA-specific T effector cells in peripheral LN, dependent 
on CD25
+ Treg cells  
CD4
+CD25
+Foxp3
+ Tregs inhibit 
Teffector cell proliferation and induce 
Teffector cell apoptosis and depletion 
[48] 
BALB/c 
mice 
Allergen 
Betv1a-
CTB 
Nasal 3 doses (20 µg) 
D0,D7,D14 
allergic sensitization with the 
allergen  
Decrease in IgE, IL-5 Increase in IgG2a, IFNγ + local IgA , Th1 shift  
Upregulation of Foxp3, IL-10 and TGFβ mRNA in splenocytes after 
pretreatment with unconjugated allergen but not with the fusion molecule 
Tolerance induction by the conjugate 
not associated with an increased 
expression of Foxp3, CTLA4 or the 
suppressive cytokines IL-10 and TGFβ 
in lymphocyte population of spleens or 
lungs 
[49] 
Abbreviations: CFA: complete Freund adjuvant; CLN: cervical lymph nodes; DTH: delayed-type hypersensibility; MLN: mesenteric lymph nodes; OVA: ovalbumin; PP: Peyer’s patches; 
SC: subcutaneously. Toxins 2010, 2 
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In conclusion, CD25
+Foxp3
+ as well as Foxp3
- and Foxp3
+CD25
-CD4
+ Treg cells have been shown 
to be induced and to exert immunosuppressive effects after immunization with Ag-CTB in allergy 
experimental models. In auto-immune disease models, TGFβ producing Tregs (Th3?) have been the 
main Treg subtype reported.  
However, the
 type of antigen or the nature of antigen-delivey system (coadministration vs Ag-conjugate) 
as well as the dose are major determinants that may lead to different, even opposite, effects 
6.1.2. b-LTB 
LTB has been less studied than CTB (Table 3). In a model of collagen- induced arthritis (CIA), 
Luross  et al.  [52]  report that ETxB (referred to LTB in this review) administered alone by the 
intranasal or the oral route, was effective in preventing collagen-induced arthritis. Disease protection 
could be transferred by CD4
+ T cells from treated mice, an effect that was abrogated upon depletion of 
the CD25
+ population. Of note, in this study, LTB was used alone and CTB failed to block CIA in the 
same conditions. The authors proposed that the inability of CTB, when used alone, to modulate CIA 
reveals critical differences between LTB and CTB, which probably relate to their disparate stabilities 
(i.e., CTB is unstable as a pentamer below pH 3.9, and LTB is stable at pH 2.0) or the slightly wider 
receptor specificity of LTB. 
Two studies reported that LTB exerts an immunomodulating effect that could be Treg-induced, as 
shown by the increase in TGFβ or IL-10, but together with an adjuvant effect. LTB abrogated oral 
tolerance to coadministered OVA in DO11.10 chimeric mice, resulting in a weak anti-OVA immune 
response, and an increase in TGFβ production [53]. In the same manner, the vaccination of latently 
HSV-1 (human herpes simplex virus type 1) infected mice with HSV-1 glycoproteins and LTB 
induced both systemic, eye and vaginal antibodies together with high levels of IL-10 and protection 
against both reactivation of latent virus and recurrent herpetic corneal epithelial disease and stromal 
disease [54]. 
Consistent with a balanced response, LTB has been reported by Raveney et al. [55] to protect mice 
from experimental auto-immune uveitis (EAU) development by inhibiting Th1 responses. 
Nevertheless, the resultant reduction in IFNγ responses by LTB does not affect infiltration or structural 
damage in established EAU, where Th17 responses predominate. However, this enhanced Th17 
activity may be controlled directly by IL-10 or by increased levels of Treg activity as Th17 infiltration 
is not associated with increased symptoms. 
Together, these results suggest that LTB like CTB induces CD25
+ as well as IL-10 and/or TGFβ 
producing Tregs, but the balance response/tolerance may be different, either because of differences 
between the two subunits, notably in receptor binding but probably also because of the nature of the 
immunogens used (Ag-CTB conjugates versus coadministered Ag /LTB in the different studies). 
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Table 3. LTB and regulatory T cells. 
Abbreviations: CIA: collagen-induced arthritis; EAU: experimental auto-immune uveitis; GP: glycoprotein; HSV-1: human herpes simplex virus type 1. 
Model  Antigen  Protocol  Effects 
Proposed Mechanism for 
Immuno-Modulation 
Reference 
DBA/1 
mice CIA 
LTB 
alone 
Nasal (100 µg) or 
intragastric (1 µg) 
transfer  
Protection against CIA at the induction or 25 days 
later (not CTB)  
Decrease in IFNγ but not in IL-4 and IL-10  
Transfer of CD4
+ T cells induces protection 
abrogated upon depletion of the CD25
+ 
population  
CD4
+CD25
+ Tregs  [52] 
DO11.10 
chimeric 
mice 
LTB + 
OVA 
Oral D1, 3, 5, and 7 
(1 mg OVA+ 20 µg 
LTB)  
Depressed IFNγ and enhanced TGFβ CTLA-4 up-
regulation 
Activated regulatory T cell 
populations as part of tolerance 
induction 
[53] 
Balb/c mice 
Latently 
infected by 
HSV-1 
Therapeutic 
vaccination 
LTB + 
HSV GP  
Nasal 3 doses at 10-
day intervals 10 µg 
HSV-1 
glycoproteins + 20 
µg LTB 
Modulation of the Th1-dominated 
proinflammatory response induced upon infection  
Increase in IL-10 production by proliferating T 
cells from LN  
Protection from HSV reactivation: decrease in 
incidence and severity of keratitis + reduction of 
virus spread + protection from encephalitis+ 
reduction in the incidence of recurrent herpetic 
corneal  
Tr1 Tregs  [54] 
B10.RIII 
EAU 
LTB 
alone 
Nasal (50 µg) 
for 4 days, starting 
either 3 days before 
or 3 days after EAU 
induction 
Preimmunization treatment protects from EAU 
decrease in Th1  
Treatment after induction does not protect despite 
decrease in IFNγ (Th1 decrease). Increases Th17 
infiltration but not symptoms 
IL-10 producing Tregs (Tr1)? 
modulate Th17 cells Critical 
importance of the dynamics of 
infiltration 
[55] Toxins 2010, 2 
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6.2. A Subunit: CTA1-DD and Mutant (Table 4) 
CTA1-DD lacks the B subunit as it comprises the A subunit of cholera toxin linked to a synthetic 
analog of S. aureus protein A. Whereas CTA1-DD has been shown to have adjuvant activity, a mutant 
of CTA1-DD, CTA1R7K-DD, that is devoid of ADP -ribosyl transferase activity has been reported to 
induce tolerance when used by the IN route as a fusion protein including either a type II collagen 
peptide or an OVA peptide [24,25]. The mechanism behind the tolerance to collagen induced arthritis 
appears to be mediated by peptide-specific regulatory T cells induced by mucosal exposure to the 
peptide containing CTA1R7K-COL-DD vector. Moreover, using a fusion protein CTA1R7K-OVA-DD, 
Hasselberg  et al.  demonstrated that ADP-ribosylation controls the outcome of tolerance or active 
effector T cell immunity as a single point mutation, resulting in lack of enzymatic activity, promoted 
peptide-specific tolerance in TCR transgenic CD4
+ T cells following a single intranasal treatment [24]. 
Table 4. CTA1-DD mutant and regulatory T cells.  
Model  Protocol  Effects 
Proposed Mechanism 
for Tolerance 
Reference 
DBA-1 
mice 
Nasal  
3 doses 5 µg on D5, 6, 7 
CTA1R7K-COL-DD 
after the collagen 
boost/induction of CIA. 
Protection against CIA 
Lower serum anti-collagen antibodies 
Decrease in IL-6, IL-17, IFNγ  
Increase in IL-10 in serum and at the 
T cell level. 
Peptide specific induced 
Tregs Tr1? 
[25] 
BALB/c 
mice 
Nasal  
CTA1R7K-OVA-DD 
Induction of long-lived specific 
tolerance to OVA,  
Induction of IL-10 Tregs Dependent 
on enzymatic activity 
Induction of CD4
+CD25
-
Foxp3
- Tr1 cells 
producing IL-10 
[24] 
Abbreviations: CIA: collagen-induced arthritis. 
6.3. Whole Toxins and Mutants (Table 5) 
Three studies have hypothesized an effect of CT on Tregs as a mechanism of adjuvanticity (Table 5). 
As early as 1995, Elson et al. [56] showed a profound reduction in CD8
+ IEL shortly after a mucosal 
exposure of mice to CT. They proposed that one of the mechanisms of CT’s mucosal effects in vivo 
was the alteration of the regulatory T cell environment in the GALT . Flach et al. [57] confirmed in 
rats that intragastric CT challenge rapidly affects CD8
+ IEL within the intestinal mucosa, but suggested 
a cell migration rather than cell death. In both studies, the immunomodulating role of CD8
+  IEL 
depletion has been suggested but not demonstrated.  
Sun et al. [46] showed an effect of CT on CD4
+ Tregs. Indeed, they found that the coadministration 
of even very small amounts of CT together with the OVA/CTB conjugate effectively prevented the 
induction of CD25
+CD4
+ suppressor T cells. Furthermore, CT also inhibited the normal suppressive 
function and Foxp3 gene expression of the mucosal CD25
+ Treg cells in the OVA/CTB-treated mice in 
comparison with PBS-fed mice. However, they observed only a relatively small effect of CT given 
after, rather than together, with a tolerizing OVA/CTB feeding regimen.  
At the opposite, Lavelle et al. [58,59] showed that parenteral immunization (footpad) of mice with 
keyhole limpet haemocyanin (KLH) in the presence of CT promoted the induction of Tr1 cells specific Toxins 2010, 2                     
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for KLH, that suppressed IFNγ production by Th1 cells as a consequence of an effect of CT on DC 
maturation and cytokine production (induction of IL-10 and inhibition of IL-12). The Tr1 
subpopulation was further characterized as producing IL-10 but not IL-4 and as acting by a cell 
independent contact mechanism [58,59]. Although the route of administration may be an important 
factor to consider, this study suggests that CT promotes Treg induction. The results we obtained with a 
protease site mutant of LT, LT-R192G, showed that it decreases CD4
+CD25
+Foxp3
+ T cells in vitro 
during a first contact (probable nTregs). However, consistent with the results of Lavelle et al.,  
LT-R192G induces specific CD4
+CD25
+Foxp3
+ T cells that can be recalled in vitro in the presence of 
LT-R192G (Foxp3 upregulation) and also promotes the induction of Ag (rotavirus-like particles)-specific 
CD4
+CD25
+Foxp3
+ T cells [60] that can be recalled in vitro in the presence of Ag (upregulation of 
both CD25 and Foxp3). Thus, the whole molecules, despite adjuvant properties, may also induce or 
promote Tregs. 
6.4. Mechanisms 
Different mechanisms, that are not exclusive, have been suggested to explain how these toxins may 
exert their effects on Tregs. They may affect either Treg number or Treg function by 1) decreasing 
Tregs 2) modulating APC thus leading to Treg induction or inhibition 3) modulating Treg interaction 
with target cells (cell-cell contact) 4) increasing the production of soluble suppressive factors such as 
IL-10 and TGFβ.  
Treg decrease. The whole toxins or their mutants that have an adjuvant effect may specifically 
decrease Treg number. However, although CT and LT have been shown to induce a depletion of CD8
+ 
IEL  [56,57]  and CD4
+  and CD8
+  lymphocytes by in vivo  apoptosis  [34], respectively, a specific 
decrease of Tregs in vivo  has not been demonstrated. We have shown a decrease of CD4
+ 
CD25
+Foxp3
+ T cells during a first in vitro contact with the mutant LT-R192G but not during an in 
vitro recall, suggesting a probable specific effect on nTregs but not on Tregs induced in immunized 
mice [60]. However, no significant decrease has been observed in vivo after a first immunization  
(data not published).  
APC modulation.  Dendritic cells (DC) play a determinant role in the orientation of immune 
responses.  Whole toxins have been shown to have many effects on DC (reviewed in [1–3]), they 
notably upregulate class II MHC as well as costimulatory molecules, leading to improved capacity to 
present antigens. Negri et al. [61] also reported that CT and LT, but not their non toxic derivates, 
improve the antigen-presenting cell function of human B lymphocytes in vitro. However, whether 
these effects render effector T cells unresponsive to suppression and/or lead to Treg inhibition has not 
been demonstrated. Similarly, GITR, which is upregulated by systemic administration of LT [36], may 
also help target cells to evade suppression or inhibit the suppressive capacity of Tregs, but as for 
costimulatory molecules, a direct impact of LT on Tregs has not been demonstrated. Anjuere et al. [62] 
found that oral administration of CT to mice resulted in a marked increase in PP and MLN of 
CD11c
+CD8
int DC with potent immunological antigen presentation, together with inhibition of the 
normal development of tolerogenic CD11c
+CD8
+B220
+  (plasmacytoid) DC in response to  CTB 
administration, but again, inhibition of Tregs was not reported. Moreover, Lavelle et al. have reported 
that CT promotes the induction of T cells with regulatory activity (Tr1) by inducing IL-10 production 
by DC and inhibiting IL-12 [59]. Toxins 2010, 2 
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Table 5. Whole toxins and mutants and regulatory T cells. 
Model  Protocol  Route  Effects  Conclusion  Reference 
C57B1/6 
or CB6F1 
mice 
CT (10 µg) or CTB  
(100 µg) + transfer of 
splenocytes from donors fed 
with CT+ KLH  
Intragastric 
IEL CD8
+ depletion in the group receiving CT  
T cell suppression of both secretory IgA and 
plasma IgG anti-KLH after KLH feeding and 
its abrogation by CT  
Abrogation of suppressor T cell function in vivo by 
mucosal CT 
Tregs non characterized 
[56] 
Rat 
CT (100 µg) or CTB  
(62 µg) 
Intragastric 
CT induces a transient depletion of jejunal 
CD8 (IEL)  
Disturbance of the gut homeostasis  
Tregs non characterized 
[57] 
Balb/c 
mice 
OVA-CTB 3 doses  
(200 µg) at 2 days of interval 
+/− CT (4 µg)  
Intragastric 
CT abrogates the increase in the frequency 
and suppressive activity of Ag-specific 
CD25
+CD4
+Foxp3
+Tregs (MLN, PP and 
spleen) induced by CTB  
CT prevents the induction of CD25
+CD4
+ 
suppressor T cells by OVA-CTB 
CT also inhibits the normal suppressive function 
and Foxp3 gene expression of the mucosal CD25
+ 
Treg cells in the OVA/CTB-treated mice  
[46] 
Cf Table 2 
BALB/c, 
C3H/He
N, and 
C3H/HeJ 
mice  
D0: KLH (10 µg) or KLH 
(10 µg) and CT (1.0 µg) D7: 
KLH  
(20 µg) Generation of Ag 
specific Tcell lines and 
clones Cocultures of DC + 
LPS + CT 
SC footpad 
Induction of Th2 and Tr1 cells (specific for 
KLH); Inhibition of IFNγ production 
DC + LPS + CT: CT induces maturation of 
DC, induces IL-10, and inhibits IL-12 
production 
CT promotes the induction of Tr1 cells specific for 
bystander Ag  
Effect on DC  
[59] 
Balb /c 
mice 
D0: LT-R192G (10 µg) + 
rotavirus VLP (10 µg) D14: 
in vitro restimulation with 
Ag, LT-R192G or both 
Intrarectal 
LT-R192G decreases in vitro 
CD4
+CD25
+Foxp3
+ from non immunized 
mice (nTregs?) 
LT-R192G induces specific 
CD4
+CD25
+Foxp3
+ and promotes the 
induction of CD4
+CD25
+Foxp3
+ specific for 
the Ag 
Effect of LT-R192G on CD4
+CD25
+Foxp3
+ Tregs, 
different between a first contact and a recall  
[60] 
Abbreviations: DC: dendritic cells; IEL: intra-epithelial lymphocytes; KLH: keyhole limpet hemocyanin; VLP: viral like particles. Toxins 2010, 2 
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Conversely to CT, CTB is expected to modulate APC leading to Treg induction. Indeed, CTB has 
been reported to induce regulatory Tr1 cells by preventing human DC maturation on the basis that it 
partially prevents LPS induced maturation of monocyte derived dendritic cells (MDDC), decreases 
their IL-12 production and, in cocultures with T cells promotes IL-10 [63]. Besides DC, B cells may 
play an important and probably underestimated role in promoting Tregs. Sun et al.,  [64]  using  
µMT−/− B cell-deficient mice, showed the importance of B cells for the induction of Ag-specific 
Foxp3
+  Treg cells and oral tolerance.  They proposed that  the high-affinity binding of CTB-Ag 
complexes to B cell (or other APC) rafts via the GM1 receptor and the exceptional persistence of such 
complexes on the cell surface may be important both for inducing tolerogenic effects in the B cells and 
possibly also immune synapse formation of B cells with Ag-specific T cells promoting the 
development and expansion of Treg cells. Of note, Thiam et al. [60] and Ogier et al. [65] observed a 
massive expansion of Ag specific B cells after mucosal immunization with rotavirus–like particles and 
LT-R192G, after a prime but not after a boost; most of them were non conventional B1-a cells 
expressing CD5. We hypothesized that this massive expansion may be suppressed by Tregs induced in 
the presence of the adjuvant. We found that CD4
+CD25
+Foxp3
+ specific for both the antigen and the 
adjuvant were induced after a prime, but the role of B cells in inducing these cells remains to be 
determined.  
In summary, as expected, CTB has been reported to modulate APC, either DC or B cells, to induce 
Tregs, but CT has also been shown to modulate APC to induce Tr1 cells.  
6.5. Direct effect on Treg-target cell interaction 
The cholera-like enterotoxins may impact on Treg-target cell interaction either by modulating 
delivery of suppressive factors via  gap junctions including cAMP, by inducing membrane-bound 
suppressive cytokines such as TGFβ or by increasing CTLA-4 expression by Tregs. 
6.5.1. cAMP  
Vendetti et al. [66] reported that CT-pretreated CD4
+ T lymphocytes can exert regulatory functions 
by inhibiting the proliferation of autologous PBMC through the release of extracellular cAMP and that 
the cyclic nucleotide acts as a primary messenger, which could play a biological role in the modulation 
of immune responses. This result is consistent with results published in 2007 by Bopp et al. [67] which 
showed that Tregs can increase cAMP levels in the target cells by delivery via gap junctions. 
6.5.2. TGFβ 
TGFβ has been shown to be induced by Ag-CTB conjugates in many studies (Tables 1 and 2). 
TGFβ is an immunosuppressive cytokine that can also contribute to cell-contact suppression when 
bound to membrane [68], however the importance of this mechanism in tolerogenicity induced by CTB 
has not been demonstrated. 
6.5.3. CTLA-4  
CT has been shown to up-regulate the expression of the inhibitory molecule CTLA-4 in naïve, 
effector and memory resting CD4
+  T cells and in resting CD8
+  T lymphocytes [66]. Tregs 
constitutively express CTLA-4 that has been shown to have a specific role in the function of Toxins 2010, 2                     
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CD4
+CD25
+ Tregs [69]. One can hypothesize that CT may also up-regulate CTLA-4 expression on 
Tregs thus modulating their function.  
In summary, although these 3 mediators that may improve Treg function are upregulated by CT 
and/or LT, an impact on Tregs has been demonstrated only for cAMP. Of note, cAMP increase is 
correlated with the enzymatic activity and thus only the whole toxins may exert an immunosuppressive 
effect via cAMP. 
7. Conclusions 
Both the whole toxins and the B subunits have been shown to modulate Tregs. Moreover, different 
mechanisms may account for their effects and, except for the mechanism involving cAMP, it is 
difficult to associate one mechanism with a type of molecule, i.e., whole toxin or mutant vs B subunit, 
thus confirming the great complexity of these molecules and the difficulty to categorize them into 
adjuvants on the one hand and tolerance inducers on the other hand. However, the recent report by 
Hasselberg et al. showing that ADP-ribosylation controls the outcome of tolerance or active effector  
T cell immunity to an internal peptide p323–339 from OVA inserted into the cholera toxin   
(CT)-derived CTA1-OVA-DD [24] demonstrates that it is possible to decipher at the molecular level 
the critical determinants that impact on the orientation of immune responses.  
Nevertheless, the variability of the effects depending on the type of antigen, the dose, the route and the 
time of administration (prime/boost or prevention/treatment) makes it imperative to test these 
molecules in different models. 
As these molecules are potent immunomodulating agents with therapeutic potential in humans, 
future research to improve understanding of their effects is necessary. 
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